ProCE Banner Activity

Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Podcast Episodes

In an engaging discussion led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Dr. Sara Hurvitz, MD, FACP, share how they currently use CDK4/6 inhibitors for their patients with metastatic HR-positive/HER2-negative breast cancer, the potential clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021, and strategies for counseling patients receiving CDK4/6 inhibitors.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Released: August 19, 2021

Expiration: August 18, 2022

No longer available for credit.

Share

Faculty

Matthew P. Goetz

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Matthew P. Goetz, MD, has disclosed that he has received consulting fees paid to his institution from Biotheranostics, Biovica, Context Pharm, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer, and Sermonix and has received funds for research support paid to his institution from Lilly, Pfizer, and Sermonix.

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Phoenix Molecular Designs, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, and Zymeworks.